Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Interest & Investment Income (2021 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 5 years of Interest & Investment Income data on record, last reported at $7.8 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 8.54% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $27.4 million, down 13.29%, while the annual FY2025 figure was $27.4 million, 13.29% down from the prior year.
  • Interest & Investment Income reached $7.8 million in Q4 2025 per VRDN's latest filing, up from $5.5 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $8.5 million in Q4 2024 and bottomed at $34000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $4.6 million, with a median of $4.8 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: surged 2399.28% in 2022, then fell 24.83% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at $138000.0 in 2021, then soared by 2399.28% to $3.4 million in 2022, then surged by 51.09% to $5.2 million in 2023, then soared by 63.5% to $8.5 million in 2024, then decreased by 8.54% to $7.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $7.8 million in Q4 2025, $5.5 million in Q3 2025, and $6.5 million in Q2 2025.